

# Randomized Trial Evaluating Radiation following Surgical Excision for “Good Risk” DCIS: 12-Year Report from NRG/RTOG 9804

B. McCormick

*Memorial Sloan Kettering Cancer Center, New York, NY*

# Disclosure for Dr. McCormick

- Author's Affiliations
  - Memorial Sloan Kettering Cancer Center (BMc), NRG Oncology Statistics and Data Management Center/ACR (KW, JM), M D Anderson Cancer Center (HK, NS, ES), Odette Cancer Centre-Sunnybrook Health Sciences Centre (ER DV), Massachusetts General Hospital (BS), L Hotel-Dieu De Quebec (IG), Dartmouth-Hitchcock Medical Center (AH), Greenville CCOP Cancer Centers of The Carolinas (MO), Henry Ford Hospital (EW), Southeast Cancer Control Consortium, Inc. CCOP ((JA), University of Michigan Medical Center (LP), Sutter Medical Center Sacramento (accruals Radiological Associates of Sacramento) (AP), University of Hawaii Cancer Research Center (KS), Ohio State University (JW)
- Grant/Sponsor Acknowledgements
  - Grant Info: U10CA180868 (NRG Operations), U10CA180822 (NRG SDMC), UG1CA189867 (NCORP) from the National Cancer Institute
  - NCT00003857

# Background

- RTOG 9804 was designed to address whether radiation therapy after breast-conserving surgery would decrease local failure (invasive, in situ) and need for mastectomy among a cohort of DCIS patients at low risk of recurrence
- Unlike previous prospective RCTs comparing whole breast radiation therapy with no RT for DCIS, RTOG 9804 included only “good risk” patients
  - Detected by mammogram, size  $\leq 2.5$  cm, final margins  $\geq 3$  mm, and low or intermediate nuclear grade

# Schema

S T R A T I F Y	<b><u>Age</u></b> 1. < 50 2. ≥ 50	R A N D O M I Z E
	<b><u>Final Path Margins</u></b> 1. Negative (re-excision) 2. 3-9 mm 3. ≥ 10 mm	
	<b><u>Mammographic/Pathologic Size of Primary</u></b> 1. ≤ 1 cm 2. > 1 cm to ≤ 2.5 cm	
	<b><u>Nuclei Grade</u></b> 1. Low 2. Intermediate	
	<b><u>Tamoxifen Use</u></b> 1. No 2. Yes	
	<b><u>Arm 1</u></b> Observation ± tamoxifen 20 mg per day for 5 years	
	<b><u>Arm 2</u></b> Radiation therapy to the whole breast, ± tamoxifen 20 mg per day for 5 years	

## Endpoints

- Local failure
- Contralateral breast failure
- Salvage mastectomy


## Median follow-up

- 12.4 years

# Patient age and pathology

	Observation (n=317)	Radiation Therapy (n=312)
<b>Age</b>		
< 50	69 (21.8%)	60 (19.2%)
≥ 50	248 (78.2%)	252 (80.8%)
<b>Final Microscopic Margins</b>		
3mm - 9mm	111 (35.0%)	110 (35.3%)
≥ 10mm	50 (15.8%)	51 (16.3%)
Negative by negative re-excision	156 (49.2%)	151 (48.4%)
<b>Mammographic Size of Primary Tumor</b>		
≤ 1cm	229 (72.2%)	223 (71.5%)
> 1cm	88 (27.8%)	89 (28.5%)
<b>Nuclei Grade</b>		
NG1	141 (44.5%)	135 (43.3%)
NG2	176 (55.5%)	177 (56.7%)


# Local failure: Ipsilateral breast



## Multivariable analysis: Local failure

Comparison	HR	p-value
Treatment: obs+tam vs RT+tam	0.25	0.0003
Age: <50 vs ≥50	0.93	0.84
Margins: neg vs 3-9mm	0.60	0.16
Margins: neg vs ≥10mm	0.37	0.098
Largest lesion: ≤0.5cm vs 0.6-1.0cm	1.14	0.72
Largest lesion: ≤0.5cm vs >1.0cm	1.81	0.16
Nuclei grade NG2 vs NG1	0.69	0.26
Tamoxifen received: no vs yes	0.50	0.024

# Contra-lateral breast events



# Mastectomy rates

Observation (n=317)	RT (n=312)
<b>17 Mastectomies (5.4%)</b> 9 ipsilateral; 0 elective 8 bilateral; 2 elective	<b>10 Mastectomies (3.2%)</b> 4 ipsilateral; 1 elective 6 bilateral; 1 elective



# Adverse events/Toxicities

## Acute Non-Hematological Toxicities

(Graded with CTC version 2.0)

Grade	Observation (n=317)	Radiation Therapy (n=312)
1	39 (12.3%)	107 (34.4%)
2	54 (17.0%)	124 (39.9%)
3	12 ( 3.8%)	11 ( 3.5%)
4	1 ( 0.3%)	2 ( 0.6%)
5	0 ( 0.0%)	0 ( 0.0%)

## Late Radiation Therapy Toxicity

(Graded with RTOG/EORTC late toxicity criteria)

Grade	Radiation Therapy (n=307)
1	90 (29.3%)
2	15 ( 4.9%)
3	3 ( 1.0%)
4	1 ( 0.3%)
5	0 ( 0.0%)

# Conclusions

- In this defined “good risk” DCIS population, the addition of whole breast radiation following breast conservation surgery significantly reduced the risk of any local recurrence and of invasive local recurrence.
- The larger-than-expected reduction has yielded meaningful results despite not meeting original targeted accrual.
- Findings should inform meaningful patient-doctor discussions about risks, benefits and the patient’s own degree of comfort, which varies greatly, with regards to local control with and without radiation therapy.